Develops therapies for pediatric cancers, focusing on epigenetic regulators and oncology treatments.
Salarius Pharmaceuticals, Inc. is a biotechnology company in the clinical stage, specializing in the development of innovative cancer treatments based on epigenetics. The company's primary focus revolves around its lead candidate, Seclidemstat (SP-2577), a small molecular inhibitor currently undergoing Phase I/II clinical trials. This promising therapy is aimed at treating advanced solid tumors and Ewing sarcoma, reflecting Salarius Pharmaceuticals' commitment to addressing critical medical needs in oncology.
In addition to Seclidemstat, Salarius Pharmaceuticals is advancing SP-3164, a small molecular protein degrader designed for the treatment of both hematological malignancies and solid tumors. The company has established strategic collaborations to support its research and development efforts. These partnerships include an exclusive license agreement with The University of Utah Research Foundation for patent rights related to SP-2577 and its derivatives, and a collaboration with HLB Life Sciences to develop and commercialize the drug in South Korea. Moreover, Salarius Pharmaceuticals colaborates with the Cancer Prevention and Research Institute of Texas and the Cancer Epigenetics Institute at Fox Chase Cancer Center to explore new indications and biomarkers for SP-2577, further expanding its therapeutic potential.
Headquartered in Houston, Texas, Salarius Pharmaceuticals, Inc. operates at the forefront of biotechnological innovation, driven by a mission to transform cancer treatment paradigms. With a strong emphasis on epigenetic mechanisms and precision medicine, the company continues to advance its pipeline of novel therapies, aiming to improve outcomes for patients worldwide battling challenging forms of cancer.